Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | LTK | P29376 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.34 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | TKT | P29401 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30918009 | 1.00 | ADORA3 (0.37) | ADORA3ADORA2AADORA2BADORA1NTRK1 | |
| SCHEMBL5468049 | 0.74 | NTRK1 (0.30) | NTRK1LTKTYRO3NTRK2CLK4 | |
| SCHEMBL743402 | 0.74 | MAPK1 (0.39) | NTRK1LTKTYRO3NTRK2CLK4 | |
| SCHEMBL15293635 | 0.72 | ADORA3 (0.46) | ADORA3ADORA2AADORA2BADORA1TKT | |
| SCHEMBL19131856 | 0.71 | XPO1 (0.32) | — | |
| SCHEMBL18671569 | 0.69 | NTRK1 (0.33) | NTRK1LTKTYRO3NTRK2CLK4 | |
| SCHEMBL29994236 | 0.69 | NTRK1 (0.41) | ADORA2AADORA1NTRK1LTKTYRO3 | |
| SCHEMBL1160659 | 0.69 | NTRK1 (0.41) | ADORA2AADORA1NTRK1LTKTYRO3 | |
| SCHEMBL5463111 | 0.69 | NTRK1 (0.33) | NTRK1LTKTYRO3NTRK2CLK4 | |
| SCHEMBL857548 | 0.69 | CLK4 (0.33) | ADORA2AADORA1NTRK1LTKTYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-10654836-B2 | Pyrimidine derivative, method for preparing same and use thereof in medicine | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2020-05-19 | — | — | US | disclosed |
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2019-09-26 | — | — | US | disclosed |
| US-20190161476-A1 | Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2019-05-30 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | ADORA3 4145/4885ADORA2A 4582/4885ADORA2B 4655/4885 |
| US-10654836-B2 | Pyrimidine derivative, method for preparing same and use thereof in medicine | FGFR4, FGFR1, FGFR2 | ADORA3 883/4885ADORA2A 1131/4885ADORA2B 910/4885 |
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | ADORA3 4145/4885ADORA2A 4582/4885ADORA2B 4655/4885 |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | ADORA3 4145/4885ADORA2A 4582/4885ADORA2B 4655/4885 |
| US-20190161476-A1 | Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine | FGFR4, FGFR1, FGFR2 | ADORA3 883/4885ADORA2A 1131/4885ADORA2B 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.